Hospitalist Doctors in New Mexico Medicare Details, Address, Contact
48 Hospitalist doctors found. Showing 41 - 48
 Mrs. Sara Lee Campbell, APRN CNS-BC Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1600 North Main, Lovington, NM 88260 Phone: 575-396-6611 Fax: 575-396-1454 |
Dr. Vineela Lavu, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 42121 Us Hwy 70, Portales, NM 88130 Phone: 575-356-6652 Fax: 575-359-6827 |
 Seunghwan Byun, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2400 Unser Blvd Se, Rio Rancho, NM 87124 Phone: 505-253-7878 |
Mr. Keshave Treebhoohun, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 2400 Unser Blvd Se, Rio Rancho, NM 87124 Phone: 505-253-1183 |
Gurdeep Singh, D.O Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3001 Broadmoor Blvd Ne, Rio Rancho, NM 87144 Phone: 505-994-7000 |
Dr. Mehul Daulat, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4001 Rodeo Rd, Santa Fe, NM 87507 Phone: 505-780-8381 Fax: 505-467-8521 |
Eileen D. Comstock, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1202 Highway 60, Socorro Hospitalist Service, Socorro, NM 87801 Phone: 505-835-1140 Fax: 505-835-8716 |
Dr. Sophie M Two Hawk, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1090 Goat Springs Rd, Taos Picuris Health Center, Taos, NM 87571 Phone: 575-758-4224 Fax: 575-751-5210 |
News Archive
Cancer Research partners with AstraZeneca and Pfizer to create clinical trial for advanced lung cancer
CANCER RESEARCH UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer - marking a new era of research into personalised medicines to treat cancer.
Agendia to provide testimony on federal regulation of laboratory developed tests
Agendia, a world leader in molecular cancer diagnostics, announced today that company CEO Dr. Bernhard Sixt will provide testimony at a public meeting on July 20 in Washington D.C. on the federal regulation of laboratory developed tests (LDTs).
Bang & Olufsen Medicom and AstraZeneca to develop new patient monitor that measures patient compliance
Bang & Olufsen Medicom has announced that it has entered into an agreement with AstraZeneca on the development of a new patient monitor that measures patient compliance.
FDA-approved drug hampers cancer metastasis in animal model, shows study
For cancer to spread, it needs a hospitable environment in distant organs. This fertile "soil" can provide a home to circulating malignant cells.
› Verified 3 days ago